One of the key therapeutic strategies adopted for primarily symptomatic AD is based on the cholinergic hypothesis targeting cholinesterase enzymes (acetylcholinesterase and butyrylcholinesterase; Cummings et al., 2007), two important enzymes from the group of serine hydrolases. Here, ACHE is linked to Alzheimer disease.